182 related articles for article (PubMed ID: 31475061)
1. Incidence of and risk factors for totally implantable vascular access device complications in patients with gastric cancer: A retrospective analysis.
Okazaki M; Oyama K; Kinoshita J; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fushida S; Ohta T
Mol Clin Oncol; 2019 Oct; 11(4):343-348. PubMed ID: 31475061
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study.
Tan L; Sun Y; Zhu L; Lei X; Liang D; Rao N; Su F; Chen K; Li S
Cancer Manag Res; 2019; 11():8379-8389. PubMed ID: 31571994
[TBL] [Abstract][Full Text] [Related]
3. Availability of totally implantable venous access devices in cancer patients is high in the long term: a seven-year follow-up study.
Tumay LV; Guner OS
Support Care Cancer; 2021 Jul; 29(7):3531-3538. PubMed ID: 33155092
[TBL] [Abstract][Full Text] [Related]
4. Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems.
Hartkamp A; van Boxtel AJ; Zonnenberg BA; Witteveen PO
Neth J Med; 2000 Dec; 57(6):215-23. PubMed ID: 11099790
[TBL] [Abstract][Full Text] [Related]
5. Internal jugular vein versus subclavian vein as the percutaneous insertion site for totally implantable venous access devices: a meta-analysis of comparative studies.
Wu S; Huang J; Jiang Z; Huang Z; Ouyang H; Deng L; Lin W; Guo J; Zeng W
BMC Cancer; 2016 Sep; 16(1):747. PubMed ID: 27658952
[TBL] [Abstract][Full Text] [Related]
6. Assessing the time-to-removal of totally implantable venous access devices comparing valved-versus open-ended catheters in patients treated with chemotherapy.
Amroun K; Brugel M; Rhaiem R; Teuma L; Vannieuwenhuyse G; Lipere A; Brenet E; Kianmanesh R; Bouché O
J Vasc Access; 2024 Jan; ():11297298231223539. PubMed ID: 38205615
[TBL] [Abstract][Full Text] [Related]
7. Totally implantable central venous access ports in patients with cystic fibrosis: a multicenter prospective cohort study.
Dal Molin A; Di Massimo DS; Braggion C; Bisogni S; Rizzi E; D'Orazio C; Di Toppa MV; Alghisi F; Cristadoro S; Carnovale V; Festa G; Rampini S; Colombo C; Oneta A; Furnari ML; Calamia MA; Zunino ML; Tuccio G; Spadea V; Messore B; Grosso B; Festini F
J Vasc Access; 2012; 13(3):290-5. PubMed ID: 22266592
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of totally implantable venous access port placement via the axillary vein in patients with head and neck malignancy.
Hong S; Seo TS; Song MG; Seol HY; Suh SI; Ryoo IS
J Vasc Access; 2019 Mar; 20(2):134-139. PubMed ID: 29923460
[TBL] [Abstract][Full Text] [Related]
9. Is there any effect of first-day usage of a totally implantable venous access device on complications?
Karanlik H; Odabas H; Yildirim I; Ozgur I; Kilic B; Sen F; Kurul S; Aydiner A
Int J Clin Oncol; 2015 Dec; 20(6):1057-62. PubMed ID: 25911604
[TBL] [Abstract][Full Text] [Related]
10. Quality-of-life assessment: arm TIVAD versus chest TIVAD.
Burbridge B; Goyal K
J Vasc Access; 2016 Nov; 17(6):527-534. PubMed ID: 27768211
[TBL] [Abstract][Full Text] [Related]
11. Totally implantable venous access devices in children with cystic fibrosis: incidence and type of complications.
Deerojanawong J; Sawyer SM; Fink AM; Stokes KB; Robertson CF
Thorax; 1998 Apr; 53(4):285-9. PubMed ID: 9741372
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Risk Factors for Totally Implantable Venous Access Device Infections in Pediatric Patients With Cancer: A Study of 25,954 Device-Days.
Lee JK; Choi YB
J Korean Med Sci; 2022 Sep; 37(35):e266. PubMed ID: 36065650
[TBL] [Abstract][Full Text] [Related]
13. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.
Biffi R; de Braud F; Orsi F; Pozzi S; Mauri S; Goldhirsch A; Nolè F; Andreoni B
Ann Oncol; 1998 Jul; 9(7):767-73. PubMed ID: 9739444
[TBL] [Abstract][Full Text] [Related]
14. Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients.
El-Balat A; Schmeil I; Karn T; Holtrich U; Mavrova-Risteska L; Rody A; Youssef A; Hanker LC
In Vivo; 2018; 32(5):1275-1281. PubMed ID: 30150457
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of totally implantable venous access devices.
Wang YC; Lin PL; Chou WH; Lin CP; Huang CH
Support Care Cancer; 2017 Jul; 25(7):2049-2054. PubMed ID: 28181014
[TBL] [Abstract][Full Text] [Related]
16. Radio-opacity and incidental identified mechanical complications of totally implantable venous access devices placed in the chest.
Surov A; Rusner C; Weigand K; John E; Spielmann RP; Behrmann C
Acta Radiol; 2012 Nov; 53(9):1035-9. PubMed ID: 23028172
[TBL] [Abstract][Full Text] [Related]
17. Complications related to totally implantable venous access devices in children and adults following lung transplantation.
Cho JK; Acord M; Goldfarb SB; Reddy SN; Goldberg HJ; Courtwright AM
Clin Transplant; 2019 Feb; 33(2):e13465. PubMed ID: 30561770
[TBL] [Abstract][Full Text] [Related]
18. Femoral Placement of Totally Implantable Venous Access Ports in Patients with Bilateral Breast Cancer.
Almasi-Sperling V; Hieber S; Lermann J; Strahl O; Beckmann MW; Lang W; Sagban TA
Geburtshilfe Frauenheilkd; 2016 Jan; 76(1):53-58. PubMed ID: 26855441
[No Abstract] [Full Text] [Related]
19. Seat belt associated central line fracture--a previously unreported complication in cystic fibrosis.
Ghayyda SN; Roland D; Cade A
J Cyst Fibros; 2008 Sep; 7(5):448-9. PubMed ID: 18455967
[TBL] [Abstract][Full Text] [Related]
20. Totally Implantable Venous Access Devices in Children Requiring Long-Term Chemotherapy: Analysis of Outcome in 122 Children from a Single Institution.
Shankar G; Jadhav V; Ravindra S ; Babu N; Ramesh S
Indian J Surg Oncol; 2016 Sep; 7(3):326-31. PubMed ID: 27651694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
